Gallacher Capital Management LLC Buys 1,237 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Gallacher Capital Management LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 28.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 5,585 shares of the biopharmaceutical company’s stock after buying an additional 1,237 shares during the period. Gallacher Capital Management LLC’s holdings in Gilead Sciences were worth $452,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nilsine Partners LLC grew its holdings in Gilead Sciences by 1.1% during the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after acquiring an additional 127 shares during the period. Etesian Wealth Advisors Inc. increased its holdings in Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after purchasing an additional 128 shares during the last quarter. Financial Counselors Inc. lifted its stake in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 128 shares during the period. Revolve Wealth Partners LLC boosted its holdings in Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares during the last quarter. Finally, Institutional & Family Asset Management LLC grew its position in shares of Gilead Sciences by 10.3% during the 3rd quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 140 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 0.8 %

GILD traded down $0.55 during trading hours on Friday, hitting $64.78. 7,822,720 shares of the company’s stock were exchanged, compared to its average volume of 7,345,331. The stock has a market cap of $80.66 billion, a price-to-earnings ratio of 179.94, a PEG ratio of 1.30 and a beta of 0.22. Gilead Sciences, Inc. has a 1-year low of $64.33 and a 1-year high of $87.86. The stock’s 50-day moving average is $70.55 and its two-hundred day moving average is $75.78. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.37 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.75%. Gilead Sciences’s dividend payout ratio is 855.56%.

Analyst Ratings Changes

A number of brokerages recently weighed in on GILD. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research report on Wednesday, April 24th. Royal Bank of Canada decreased their price target on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a report on Friday, April 26th. Maxim Group dropped their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday. TD Cowen decreased their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Finally, Morgan Stanley cut their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $83.69.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.